RXRX FY 2021 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+193.0% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$183M-1827.8% margin

Net Income

-$186M-1864.8% margin

EPS (Diluted)

$-1.05

Cash Flow

Operating Cash Flow

-$159M

Free Cash Flow

-$198M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$610M

Total Liabilities

$67M

Stockholders' Equity

$543M

Cash & Equivalents

$285M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$3M	+193.0%
Gross Profit	$10M	$3M	+193.0%
Operating Income	-$183M	-$85M	-116.0%
Net Income	-$186M	-$87M	-114.3%